Corbus Pharmaceuticals Holdings Inc
Change company Symbol lookup
Select an option...
CRBP Corbus Pharmaceuticals Holdings Inc
SBLK Star Bulk Carriers Corp
FFBC First Financial Bancorp
HRC Hill-Rom Holdings Inc
QRTEB Qurate Retail Inc
GGN GAMCO Global Gold, Natural Resources & Income Trust
GGN GAMCO Global Gold, Natural Resources & Income Trust
GFY Western Asset Variable Rate Strategic Fund Inc
GE General Electric Co
GDXJ VanEck Vectors Junior Gold Miners ETF
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Corbus Pharmaceuticals Holdings, Inc. is a Phase-III, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and halt fibrotic processes. Lenabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing lenabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).

Closing Price
$6.71
Day's Change
-0.31 (-4.42%)
Bid
--
Ask
--
B/A Size
--
Day's High
7.10
Day's Low
6.32
Volume
(Heavy Day)
Volume:
1,114,601

10-day average volume:
871,570
1,114,601
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Social data discovery, filtering, and analysis provided by LikeFolio: © SwanPowers, LLC

Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.

TD Ameritrade provides access to social media platforms on an "as is" basis, and cannot guarantee that content from social media is always available, that it contains all content from the social media source, or that it contains the most recent or most relevant information from the source.